News

Starting a pulmonary rehabilitation program within three months of hospitalization for chronic obstructive pulmonary disease, or COPD, improved the rate of survival over one year by 6.7%, according to new research. The study, “Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year…

Having small airways compared to lung size may contribute to the development of chronic obstructive pulmonary disease (COPD) in many non-smokers, a retrospective study has found. The finding broadens understanding of the risk factors involved in COPD, say  Columbia University Irving Medical Center researchers, whose work, “Association of Dysanapsis…

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…

Following a stop due to the COVID-19 pandemic, the Medical University of South Carolina (MUSC) has become the first medical center to restart the AIRFLOW-3 clinical trial, which is testing a procedure called targeted lung denervation as a potential therapy for chronic obstructive pulmonary disease (COPD). “We’re…

Remestemcel-L, Mesoblast’s lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease (COPD) and a high degree of inflammation, data from a post-hoc analysis of a Phase 2 trial show. Findings were presented in an…

Smokers and people with chronic obstructive pulmonary disease (COPD) are more likely to develop severe complications and die from COVID-19 infections than infected patients who do not smoke or have COPD, a recent meta-analysis shows. This research, however, suggests that the prevalence of COPD patients and smokers among…

Chronic obstructive pulmonary disease (COPD) is linked to a higher risk of lung cancer in people who never smoked. In fact, their risk is equivalent to current or former smokers who do not have COPD, a research team reports. The study, “Chronic obstructive pulmonary disease…

Pulmonx’s  Zephyr Endobronchial Valve significantly reduces breathlessness and improves physical activity and quality of life in people with severe emphysema, a post-hoc analysis of clinical trial data shows. The study, “Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One…